Reducing scheduled phlebotomy in stable pediatric patients with blunt liver or spleen injury

Jamie Golden1, Ian Mitchell1, Sally Kuzniewski1

  • 1Steven and Alexandra Cohen Children's Medical Center, New Hyde Park, New York.

Insights

A new pathway for pediatric liver/spleen injuries reduces blood draws and intensive care unit (ICU) admissions. This approach uses clinical parameters, suggesting serial phlebotomy may be unnecessary for managing these injuries.

Area of Science:

  • Pediatric Surgery
  • Trauma Management
  • Clinical Pathway Development

Background:

  • Established guidelines exist for pediatric liver and spleen injuries.
  • Optimal frequency for phlebotomy (blood draws) in these patients remains undetermined.
  • Current practices may involve excessive blood testing.

Purpose of the Study:

  • To propose and evaluate a novel management pathway for pediatric solid organ injuries.
  • Hypothesize that current phlebotomy frequency exceeds necessity.
  • Aim to reduce resource utilization through a streamlined approach.

Main Methods:

  • Retrospective analysis of 120 pediatric solid organ injury cases from two hospital registries (2008-2012).
  • Comparison of resource utilization between current management and a proposed pathway.
  • Statistical analysis using paired t-test to assess differences.

Main Results:

  • Sixty-one patients (35 spleen, 22 liver, 4 combined) were analyzed.
  • The proposed pathway could decrease intensive care unit (ICU) admissions by 65% and blood draws by 70%.
  • Length of stay decreased by 37%, with all transfusions identified via hemodynamic status.

Conclusions:

  • Clinical parameters can effectively identify pediatric patients needing intervention for liver/spleen injuries.
  • Serial phlebotomy appears unnecessary, potentially reducing resource utilization.
  • The proposed pathway warrants prospective validation for clinical implementation.
Abstract

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
382
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
882
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
409